Characteristics of the study population by type of cancer.

Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

The Cancer Registries (RT) are structures responsible for the collection and registration of all tumors occurring in a given territory. The primary role of a Cancer Registry is to establish and manage over time an archive of all new cancer cases diagnosed and to ensure that the data is recorded rigorously and continuously and systematically.
Most of the Italian registers are population registers, that is, they collect data relating to cancer diseases of all the residents of a given territory (it can be a single city or an entire region, a province or the territory of an ASL).
Alongside the general population registers, there are specialized registers, which collect information on a single type of tumor or on specific age groups or on occupational cancers.

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

National Cancer Registry Ireland is a book publisher. They published 2 books in our database by 2 different authors between 2006 and 2008.

National Cancer Institute’s Cancer registry is a nationwide and population-based cancer registry, which covers all territory of Lithuania and it collects information about all new cancer cases (ICD-10-AM codes: C00-C96, D00-D09, D32-D33, D39.1, D42-D43, D45-D47) of all cancer patients.

The main task of the Cancer Registry is to guarantee as complete and reliable registration of incident cancer cases as possible.

In 1984 the Lithuanian Cancer Registry was established at the National Cancer Institute by the Order of the Minister of Health. The population-based Cancer Registry was set up in 1990.

The aims of this register are 1)To collect data, keep a register and follow up all residents of the Maltese Islands who are diagnosed with cancer, and 2)To provide a surveillance function by using registry data to examine trends by age and gender, by cancer type, over time and across the nation. The first attempts at cancer registration in Malta were started in the mid-1960s. In fact, cancer incidence data from Malta for the time period 1969-1972 were included in the Cancer Incidence in Five Continents, Volume III (IARC, 1976). The present registry started in 1985 and is still ongoing. Initially, only data on cases diagnosed at St. Luke’s Hospital (the major acute general public hospital in Malta at the time) were collected. However, since 1991, the registry has also been collecting data on cases diagnosed in all (public and private) hospitals, clinics and laboratories on the Maltese Islands. Data on cancer site and morphology is coded using the International classification of diseases for oncology (ICD-O) – version 3, revision 2.

The Welsh Cancer Intelligence & Surveillance Unit (WCISU) is the National Cancer Registry for Wales and its primary role is to record, store and report on all incidence of cancer for the resident population of Wales wherever they are treated. Cancer registration in Wales began almost five decades ago and today’s electronic database which holds records going back to 1972 contains in the region of 686,000 records.

WCISU collects data about occurrences of cancer in Welsh residents via direct or indirect submissions from Welsh Hospitals.

Staging of malignant melanoma (ICD 10 code C43), breast (C50), colorectal (C18-C20) and cervix (C53) started in 2001 since this was when we started receiving pathological information. Staging for all other cancers started in 2010.

Treatment information started in 1995.

Population-based cancer registry, member of the IACR and ENCR; collecting data on all new cases of cancer.

The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

The US National Cancer Institute (NCI) maintains and administers data elements, forms, models, and components of these items in a metadata registry referred to as the Cancer Data Standards Registry and Repository, or caDSR.

The data from the Dutch Cancer Registry (NKR) provide insights into improving care for people with cancer.

The NKR includes information about diagnostics, diagnosis, tumor characteristics and initial treatment, regardless of the treatment location. For an increasing number of cancer types, follow-up data are also available for subsequent treatments. The data is collected by specially trained IKNL data managers in hospitals based on information in the medical file. Since 1989, the database contains data from patients from all over the Netherlands.

CPRD GOLD linked National Cancer Registration and Analysis Service (NCRAS) cancer registration data contain a record for each notified, registrable tumour, diagnosed or treated in England.

Predictors of pathologic complete response following NAC.

Difference-in-differences analysis for receipt and time to treatment among young breast cancer patients, NCDB 2007–2013.

The Belgian Cancer Registry collects information about all new cancer diagnoses in Belgium and their follow-up. Based on this information it maps out the nature and extent of cancer in Belgium. It regularly bundles this information in a publication. The Belgian Cancer Registry also collects all anatomopathological test results as part of the early screening programs for certain cancers (cervical cancer, breast and colon cancer).

The Belgian Cancer Registry data are an important source of information for

• Report
  • on the incidence and prevalence of different types of cancer
  • on patient survival
  • for international organisations such as the World Health Organisation (WHO) and the International Agency for Research on Cancer (IARC)
• Studying the etiology of cancer
• Evaluation
  • of cancer screening programmes
  • of quality of treatment
• Analysis of the geographical distribution of
  • different types of cancer
  • cancer incidence
  • trends
  • outcome

Background: The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer.

Methods: From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. This dataset includes the low-dose CT scans from 26,254 of these subjects, as well as digitized histopathology images from 451 subjects.

Results: The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02).

Conclusions: Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385).

Data Availability: A summary of the National Lung Screening Trial and its available datasets are provided on the Cancer Data Access System (CDAS). CDAS is maintained by Information Management System (IMS), contracted by the National Cancer Institute (NCI) as keepers and statistical analyzers of the NLST trial data. The full clinical data set from NLST is available through CDAS. Users of TCIA can download without restriction a publicly distributable subset of that clinical data, along with the CT and Histopathology images collected during the trial. (These previously were restricted.)

An examination of national cancer risk based on monitored hazardous ambient air pollutants. This dataset is associated with the following publication: Weitekamp, C., M. Lein, M. Strum, M. Morris, T. Palma, D. Smith, L. Kerr, and M. Stewart. An Examination of National Cancer Risk Based on Monitored Hazardous Air Pollutants. ENVIRONMENTAL HEALTH PERSPECTIVES. National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC, USA, 129(3): 1-12, (2021).

The Veterans Affairs Central Cancer Registry (VACCR) receives and stores information on cancer diagnosis and treatment constraints compiled and sent in by the local cancer registry staff at each of the 132 Veterans Affairs Medical Centers that diagnose and/or treat Veterans with cancer. The information sent is encoded to meet the site-specific requirements for registry inclusion as established by several oversight bodies, including the North American Association of Central Cancer Registries, the American College of Surgeons' Commission on Cancer, and the American Joint Commission on Cancer, among others. The information is obtained from a wide variety of medical record documents at the local medical center pertaining to each Veterans Health Administration (VHA) cancer patient. The information is then transmitted to the VACCR. Details collected include extensive demographics, cancer identification, extent of disease and staging, first course of treatment, and outcomes. Data extraction is available to researchers with VA approved Institutional Review Board studies, peer review, and Data Use Agreements.